Due: March 5, 2026
The goal of this Notice of Funding Opportunity (NOFO) is to accelerate the establishment of effective and reliable biomarkers of Alzheimers disease (AD) and AD-related dementias (ADRD) for usein therapy/medical product discovery and development, clinical trials and/or clinical practice. Specifically, this NOFO willsupport analytical and/or clinical validation of a biomarker, composite biomarker or biomarker signature, with rigor comparable with the expectations described in the Food and Drug Administration (FDA) Biomarker Qualification Program (BQP) or recommended by other FDA regulatory pathways.